AI Insight
Researchers from Vanderbilt Health, UTHealth Houston, and the University of North Carolina at Chapel Hill have discovered early biomarkers in blood proteins that can identify cardiovascular-kidney-metabolic disease (CKMD) risk in children as young as 8 years old. The study suggests these early warning signs may be addressable through intervention with newer weight-loss medications that have proven effective in adult populations.
Why it matters
Early detection of CKMD risk factors in childhood could enable preventive interventions before irreversible damage occurs. The potential application of weight-loss drugs in pediatric populations represents a new therapeutic avenue for addressing metabolic disease trajectories that begin in childhood.
Understand the Science
Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight-loss drugs widely used by adults.
Source: Early blood protein clues could identify children at risk of cardiometabolic disease